[Des-Arg9]-Bradykinin acetate是缓激肽 B1 受体的激动剂，选择性高于 B2 受体。

Icatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively.

ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM.

SSR240612 is a potent and selective non-peptide bradykinin B1 receptor antagonist with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.

Bradykinin is a pro-inflammatory polypeptide. It is an important mediator of hyperalgesia, inflammatory diseases, asthma and cancer with anti-cancer activities. Targeting the bradykinin system by either blocking the bradykinin production may open a new potential therapeutic window for the treatment of COVID-19 induced acute respiratory distress syndrome (ARDS) particularly before patients enter the irreversible stages.

Bradykinin (acetate)是一种生物活性肽，具有调节血管舒缩和炎症反应的作用，可能用于研究与心血管和炎症相关的疾病。

Bradykinin (1-6), an amino-truncated bradykinin peptide, is stable metabolite of bradykinin cleaved by carboxypeptidase Y (CPY).